- Home
- AVIR vs III Comparison
AVIR vs III Comparison
Compare AVIR & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- III
- Stock Information
- Founded
- AVIR 2012
- III 2006
- Country
- AVIR United States
- III United States
- Employees
- AVIR N/A
- III N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- III Professional Services
- Sector
- AVIR Health Care
- III Consumer Discretionary
- Exchange
- AVIR Nasdaq
- III Nasdaq
- Market Cap
- AVIR 273.0M
- III 227.5M
- IPO Year
- AVIR 2020
- III 2007
- Fundamental
- Price
- AVIR $3.67
- III $4.66
- Analyst Decision
- AVIR Hold
- III Buy
- Analyst Count
- AVIR 1
- III 1
- Target Price
- AVIR $6.00
- III $5.50
- AVG Volume (30 Days)
- AVIR 410.2K
- III 183.2K
- Earning Date
- AVIR 08-06-2025
- III 08-04-2025
- Dividend Yield
- AVIR N/A
- III 3.79%
- EPS Growth
- AVIR N/A
- III N/A
- EPS
- AVIR N/A
- III 0.16
- Revenue
- AVIR N/A
- III $242,899,000.00
- Revenue This Year
- AVIR N/A
- III N/A
- Revenue Next Year
- AVIR N/A
- III $5.08
- P/E Ratio
- AVIR N/A
- III $30.34
- Revenue Growth
- AVIR N/A
- III N/A
- 52 Week Low
- AVIR $2.46
- III $2.94
- 52 Week High
- AVIR $4.15
- III $5.05
- Technical
- Relative Strength Index (RSI)
- AVIR 76.11
- III 48.97
- Support Level
- AVIR $3.15
- III $4.51
- Resistance Level
- AVIR $3.35
- III $4.79
- Average True Range (ATR)
- AVIR 0.13
- III 0.13
- MACD
- AVIR 0.03
- III -0.04
- Stochastic Oscillator
- AVIR 83.81
- III 30.56
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.